Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7947-7955

  Ricart, Alejandro D ^a   Berlin, Jordan D ^b   Papadopoulos, Kyriakos P ^a   Syed, Samira ^a   Drolet, Daniel W ^c   Quaratino Baker, Charlotte ^c   Horan, Julie ^c   Chick, Jon ^c   Vermeulen, Wendy ^b   Tolcher, Anthony W ^a   Rowinsky, Eric K ^a   Rothenberg, Mace L ^b  

^a CTRC Institute for Drug Development   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c OSI PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; OSI 7904L; UNCLASSIFIED DRUG; ((S) 2 (5 (1,2 DIHYDRO 3 METHYL 1 OXOBENZO(F) QUINAZOLINE 9 YL)METHYL)AMINO 1 OXO 2 ISOINDOLYNYL) GLUTARIC ACID; ((S)-2-(5-(1,2-DIHYDRO-3-METHYL-1-OXOBENZO(F)-QUINAZOLINE-9-YL)METHYL)AMINO-1-OXO-2-ISOINDOLYNYL)-GLUTARIC ACID; GLUTARIC ACID DERIVATIVE; HOMOCYSTEINE; ISOINDOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SAFETY; DYSGEUSIA; ENTEROPATHY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERBILIRUBINEMIA; ILEUS; KIDNEY FAILURE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SEPSIS; SOLID TUMOR; STOMACH ADENOCARCINOMA; STOMATITIS; UNSPECIFIED SIDE EFFECT; VOMITING; BLOOD; GENETICS; GENOTYPE; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; NEOPLASM; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; GENOTYPE; GLUTARATES; HOMOCYSTEINE; HUMANS; ISOINDOLES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINAZOLINES; THYMIDYLATE SYNTHASE;

EID: 59449093705     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0864     Document Type: Article

References (55)

1. Carreras CW, Santi DV. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 1995;64:721-62.
2. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957;179:663-6.
3. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-AlpdoganT, Gorlick R, Bertino JR. Novel aspects of re-sistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 2002;1587:164-73.
4. Berg RW, Ferguso PJ, DeMoor JM, Vincen MD, Koropatnick J. The means to an end of tumor cell resistance to chemotherapeutic drugs targeting thymi-dylate synthase:shoot the messenger. Curr Drug Targets 2002;3:297-309.
5. Grem J. 5-Fluoropyrimidines. In:Chabner B, Longo D, editors. Cancer chemotherapy and biotherapy:principles and practice. 3rd ed. Philadelphia:Lippin-cott Williams &Wilkins;2001. p. 185-254.
6. Duch DS, Banks S, Dev IK, et al. Biochemical and cellular pharmacology of 1843U89, a novel benzoquina-zoline inhibitor of thymidylate synthase. Cancer Res 1993;53:810-8.
7. Dev IK, Dallas WS, Ferone R, Hanlon M, McKee DD, Yates BB. Mode of binding of folate analogs to thymidylate synthase. Evidence for two asymmetric but interactive substrate binding sites. J Biol Chem 1994;269:1873-82.
8. Hanlon MH, Ferone R. In vitro uptake, anabolism, and cellular retention of1843U89 and other benzoquina-zoline inhibitors of thymidylate synthase. Cancer Res 1996;56:3301-6.
9. Schwartz G, Johnson TR, Goetz A, et al. A phase I and pharmacokinetic study of 1843U89, a noncom-petitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies. Clin Cancer Res 2001;7:1901-11.
10. Desjardins J, Emerson DL, Colagiovanni DB, Abbott E, Brown EN, Drolet DW. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(s)-2-[5-[(1,2-dihy-dro-3-methyl-1- oxobenzo[f]quinazolin-9-yl)methy-l]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice. J Pharmacol ExpTher 2004;309:894-902.
11. Desjardins JP, Abbott EA, Emerson DL, et al. Biodis-tribution of NX211, liposomal lurtotecan, in tumor-bearing mice. Anticancer Drugs 2001;12:235-45.
12. Emerson D, Abbott B, Brown E., et al. In vivo anti-tumor activity and biodistribution of GS 7904L, a low clearance liposomal formulation of a novel thymidylate synthase inhibitor [abstract 1060]. Proc Am Assoc Cancer Res 2002;43:211-2.
13. Emerson D, Abbott B, Ashvar C, et al.GS7904L,a low clearance, liposomal formulation of the thymidy-late synthase inhibitor GS 7904 demonstrates enhanced pharmacokinetics and improved antitumor efficacy [abstract 448]. Proc AACR NCI EORTC Conference 7 2001;92.
14. Beutel G, Glen H, Schoffski P, et al. Phase I studyof OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors. Clin Cancer Res 2005;11:5487-95.
15. Falk S, Anthoney A, Eatock M, et al. Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer 2006;95:450-6.
16. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid:markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-52.
17. Diasio R. Pharmacogenetics. In:Chabner B, Longo D, editors. Cancer chemotherapy and biotherapy:principles and practice. 3rd ed. Philadelphia:Lippin-cott Williams &Wilkins;2001. p. 998-1011.
18. Evans WE, Relling MV. Pharmacogenomics:translating functional genomics into rational therapeutics. Science1999;286:487-91.
19. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ. Thymidylate synthase genepoly-morphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 2002;17:46-9.
20. Winski S, Srebernak M,Tomkinson B, Emerson D. In vivo efficacy of the novel thymidylate synthase inhibitor, OSI-7904L, in combination with cisplatin or oxaliplatin in xenograft models [abstract 5381]. Proc Am Assoc Cancer Res 2004;45.
21. Al Sarraf M, LeBlanc M, Giri PG, et al. Chemoradio-therapy versus radiotherapy in patients with advanced nasopharyngeal cancer:phase III randomized Inter-group Study 0099. J Clin Oncol 1998;16:1310-7.
22. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. PhaseIII study of pemetrexed in combination with cis-platin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
23. Ichinose Y, Yoshimori K, Sakai H, et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer:a multi-institutional phase II trial. Clin Cancer Res 2004;10:7860-4.
24. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural meso-thelioma:an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-9.
25. Ajani JA, Lee FC, Singh DA, et al. Multicenterphase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction ade-nocarcinoma. J Clin Oncol 2006;24:663-7.
26. Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM. Homocysteine and other thiols in plasma and urine:automated determination and sample stability. Clin Chem 1993;39:263-71.
27. HorieN,AibaH,OguroK,HojoH,TakeishiK. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct1995;20:191-7.
28. Kawakami K,Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 2003;63:6004-7.
29. Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 5′tandem repeat polymorphism of the thymidylate syn-thase gene abolishes USF-1 binding and alters tran-scriptional activity. Cancer Res 2003;63:2898-904.
30. Skibola CF, Smith MT, Kane E, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A1999;96:12810-5.
31. Noe D. Noncompartmental pharmacokinetic analysis. In:Grochow L, Ames M, editors. A clinician's guide to chemotherapy:pharmacokinetics and phar-macodynamics. Baltimore:Williams &Wilkins;1998. p. 515-30.
32. Gmeiner WH. Novel chemical strategies for thymi-dylate synthase inhibition. Curr Med Chem 2005;12:191-202.
33. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93.
34. O'ShaughnessyJ, Miles D,Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer:phase III trial results. J Clin Oncol 2002;20:2812-23.
35. Van Cutsem E,Twelves C, CassidyJ, et al. Oral cape-citabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer:results of a large phase III study. J Clin Oncol 2001;19:4097-106.
36. DouillardJY, HoffPM, SkillingsJR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605-16.
37. Carmichael J, PopielaT, Radstone D, et al. Randomized comparative study of tegafur/uracil and oral leu-covorin versusparenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorec-tal cancer. J Clin Oncol 2002;20:3617-27.
38. Schoffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 2004;15:85-106.
39. Cunningham D, Zalcberg JR, Rath U, et al. ''Tomu-dex''Colorectal Cancer Study Group. Final results of a randomised trial comparing "Tomudex" (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colo-rectal cancer. Ann Oncol 1996;7:961-5.
40. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22: 1589-97.
41. Cunningham D, Starling N, Rao S, et al. Capecita-bine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
42. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357: 1810-20.
43. Johnson LF. Posttranscriptional regulation of thy-midylate synthase gene expression. J Cell Biochem 1994;54:387-92.
44. Keyomarsi K, Samet J, Molnar G, Pardee AB. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. J Biol Chem 1993;268:15142-9.
45. Pestalozzi BC, McGinn CJ, Kinsella TJ, et al. Increased thymidylate synthaseprotein levels are principally associated with proliferation but not cell cycle phase in asynchronous human cancer cells. BrJ Can-cer1995;71:1151-7.
46. PetersGJ,Smitskamp-WilmsE,Smid K,PinedoHM, Jansen G. Determinants of activity of the antifolate thymidylate synthase inhibitors To mudex (ZD1694) and GW1843U89 against mono-and multilayered colon cancer cell lines under folate-restricted conditions. Cancer Res1999;59:5529-35.
47. Derenzini M, Montanaro L,Trere D, et al. Thymidylate synthase protein expression and activity are related to the cell proliferation rate in human cancer cell lines. Mol Pathol 2002;55:310-4.
48. Kaye SB. Clinical drug resistance:the role of factors other than P-glycoprotein. Am J Med 1995;99:40-4S.
49. Schmoll HJ, Buchele T, Grothey A, Dempke W. Where do we stand with 5-fluorouracil? Semin Oncol 1999;26:589-605.
50. Meta-Analysis Group in Cancer. Efficacy of intrave-nous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301-8.
51. Meta-Analysis Group in Cancer. Toxicity of fluoro-uracil in patients with advanced colorectal cancer:effect of administration schedule and prognostic factors. J Clin Oncol 1998;16:3537-41.
52. Banks SD, Waters KA, Barrett LL, Dickerson S, Pendergast W, Smith GK. Destruction of WiDr multi-cellular tumor spheroids with the novel thymidylate synthase inhibitor 1843U89 at physiological thymi-dine concentrations. Cancer Chemother Pharmacol 1994;33:455-9.
53. Seymour L, Eisenhauer E. A review of dose-limiting events in phase I trials:antimetabolites show unpredictable relationships between dose and toxicity. Cancer Chemother Pharmacol 2001;47:2-10.
54. Calvert H. Folate status and the safety profile of antifolates. Semin Oncol 2002;29:3-7.
55. Clamp AR, Schoffski P, Valle JW, et al. A phase I and pharmacokinetic study of OSI-7904L, a liposo-mal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 2008;61:579-85.